Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 18/20 | 1.00 |
| ▸ | MMP1 | P03956 | 18/20 | 1.00 |
| ▸ | MMP9 | P14780 | 4/20 | 1.00 |
| ▸ | MMP2 | P08253 | 10/20 | 0.98 |
| ▸ | MMP8 | P22894 | 5/20 | 0.80 |
| ▸ | MMP7 | P09237 | 7/20 | 0.76 |
| ▸ | FCER2 | P06734 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639291 | 0.99 | MMP3 (1.00) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL8480892 | 0.94 | MMP3 (0.89) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL8484210 | 0.94 | MMP3 (0.89) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL8487053 | 0.91 | MMP3 (0.84) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL8482048 | 0.91 | MMP3 (0.84) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL8479923 | 0.91 | MMP3 (0.83) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL8828119 | 0.91 | MMP1 (0.83) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL2639074 | 0.89 | MMP3 (1.00) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL8484818 | 0.89 | MMP3 (0.80) | MMP3MMP1MMP9MMP2MMP8 | |
| SCHEMBL8484275 | 0.88 | MMP3 (0.79) | MMP3MMP1MMP9MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-H09509662-A | — | — | 1997-09-30 | — | — | JP | claimed |
| US-5618844-A | MATRIX METALLOPROTEINASE INHIBITOR | SANOFI S.A. (FR) | 1997-04-08 | — | — | US | claimed |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0749302-A4 | HYDROXAMIC ACID AND CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | SANOFI WINTHROP INC (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5618844-A | MATRIX METALLOPROTEINASE INHIBITOR | SANOFI S.A. (FR) | 1997-04-08 | — | — | US | disclosed |
| EP-0749302-A1 | HYDROXAMIC ACID AND CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5514716-A | MATRIX METALLOPROTEINASE INHIBITORS, ANTIARTHRITIC | STERLING WINTHROP, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995022966-A1 | HYDROXAMIC ACID AND CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | SANOFI WINTHROP, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MMP1 20/4885MMP9 1/4885 |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | MMP8, MMP1, TIMP3 | MMP3 11/4885MMP1 2/4885MMP9 4/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MMP1 20/4885MMP9 1/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MMP1 20/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.